C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome (NCT07527130) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome
United States10 participantsStarted 2026-05
Plain-language summary
The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Mayo Clinic patients with a previously confirmed infection with the novel SARS-CoV-2 virus who have been seen in the Post COVID Clinic through GIM Integrative Medicine \& Health Section or approval by MAGPIES research group.
* Be able to participate fully in all aspects of the study.
* Have understood and signed study informed consent.
Exclusion Criteria:
* Lacking the capacity to consent.
* Prisoners and institutionalized individuals.
* Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the LLLT treatment phase and are unwilling to use a reliable form of contraception.
o Acceptable forms include:
* Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants
* Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm)
* Intrauterine device (IUD)
* Total hysterectomy or tubal ligation
* Abstinence (no sex).
* Those patients that have implants that would prevent them from having a PET Scan.
* Patients that have claustrophobia.
* Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.